These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 18230248

  • 1. Successful use of rifampicin for Hispanic foreign-born patients with latent tuberculosis infection.
    Haley CA, Stephan S, Vossel LF, Sherfy EA, Laserson KF, Kainer MA.
    Int J Tuberc Lung Dis; 2008 Feb; 12(2):160-7. PubMed ID: 18230248
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin.
    Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB.
    Chest; 2006 Dec; 130(6):1712-7. PubMed ID: 17166986
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus?
    Tortajada C, Martínez-Lacasa J, Sánchez F, Jiménez-Fuentes A, De Souza ML, García JF, Martínez JA, Caylà JA, Tuberculosis Prevention Working Group.
    Int J Tuberc Lung Dis; 2005 Mar; 9(3):276-81. PubMed ID: 15786890
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment.
    Trajman A, Long R, Zylberberg D, Dion MJ, Al-Otaibi B, Menzies D.
    Int J Tuberc Lung Dis; 2010 May; 14(5):551-9. PubMed ID: 20392347
    [Abstract] [Full Text] [Related]

  • 12. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics.
    Lee AM, Mennone JZ, Jones RC, Paul WS.
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):995-1000. PubMed ID: 12475146
    [Abstract] [Full Text] [Related]

  • 13. Acceptance of screening and completion of treatment for latent tuberculosis infection among refugee claimants in Canada.
    Levesque JF, Dongier P, Brassard P, Allard R.
    Int J Tuberc Lung Dis; 2004 Jun; 8(6):711-7. PubMed ID: 15182140
    [Abstract] [Full Text] [Related]

  • 14. Tuberculosis among foreign-born persons in New York City, 1992-1994: implications for tuberculosis control.
    Tornieporth NG, Ptachewich Y, Poltoratskaia N, Ravi BS, Katapadi M, Berger JJ, Dahdouh M, Segal-Maurer S, Glatt A, Adamis R, Lerner C, Armstrong D, Weiner M, D'Amato R, Kiehn T, Lavie S, Stoeckle MY, Riley LW.
    Int J Tuberc Lung Dis; 1997 Dec; 1(6):528-35. PubMed ID: 9487451
    [Abstract] [Full Text] [Related]

  • 15. Use of intermittent rifampin and pyrazinamide therapy for latent tuberculosis infection in a targeted tuberculin testing program.
    Priest DH, Vossel LF, Sherfy EA, Hoy DP, Haley CA.
    Clin Infect Dis; 2004 Dec 15; 39(12):1764-71. PubMed ID: 15578397
    [Abstract] [Full Text] [Related]

  • 16. Risk of tuberculosis in screened subjects without known risk factors for active disease.
    Cook VJ, Hernández-Garduño E, Elwood RK.
    Int J Tuberc Lung Dis; 2008 Aug 15; 12(8):903-8. PubMed ID: 18647449
    [Abstract] [Full Text] [Related]

  • 17. Clinical characteristics of tuberculosis in patients with liver cirrhosis.
    Cho YJ, Lee SM, Yoo CG, Kim YW, Han SK, Shim YS, Yim JJ.
    Respirology; 2007 May 15; 12(3):401-5. PubMed ID: 17539845
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Risk factors for failure to complete a course of latent tuberculosis infection treatment in Salvador, Brazil.
    Machado A, Finkmoore B, Emodi K, Takenami I, Barbosa T, Tavares M, Reis MG, Arruda S, Riley LW.
    Int J Tuberc Lung Dis; 2009 Jun 15; 13(6):719-25. PubMed ID: 19460247
    [Abstract] [Full Text] [Related]

  • 20. Tuberculosis in a low-incidence US area: local consequences of global disruptions.
    Lobato MN, Mohamed MH, Hadler JL.
    Int J Tuberc Lung Dis; 2008 May 15; 12(5):506-12. PubMed ID: 18419885
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.